Soligenix, Inc. — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments; revenue was principally from NIH grants.
Financial results
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $762,851 | $405,820 | $1,410,269 | $1,213,825 |
| Gross profit | $146,521 | $56,309 | $237,368 | $310,277 |
| Gross margin | 19.2% | 13.9% | 16.8% | 25.6% |
| Operating expenses | $1,128,198 | $1,989,099 | $2,660,035 | $3,965,913 |
| Net loss | $979,878 | $1,931,317 | $2,418,633 | $3,651,728 |
| Basic and diluted loss per share | $0.09 | $0.18 | $0.22 | $0.34 |
At June 30, cash and cash equivalents were $4.43 million, down 26% from $6.00 million at December 31, 2011. Working capital was $3.63 million, versus $5.70 million at year-end. Operating cash use was $1.56 million in the first half, compared with $3.51 million in the prior-year period; investing cash use was $4,755, with no financing cash flow. Total assets were $5.91 million and current liabilities $1.29 million. The balance sheet presents no debt balance. No profit or positive operating cash flow was reported.
Changes and operating developments
- Q2 revenue rose 88% and first-half revenue rose 16%, primarily from higher NIH grant activity. First-half gross profit declined 23%, reflecting prior-year reimbursement of certain salary costs.
- Research and development expense fell 67% in Q2 and 52% for the first half, mainly after discontinuation of the orBec Phase 3 acute GI GVHD trial. General and administrative expense increased 32% in Q2 and 19% for the first half.
- The confirmatory Phase 3 trial of orBec for acute GI GVHD was stopped in September 2011 after showing no difference from placebo on primary or prespecified secondary endpoints; development for that indication was terminated.
- Development priorities included SGX203 for pediatric Crohn’s disease, SGX201 for radiation enteritis, RiVax, VeloThrax, ThermoVax and OrbeShield. The filing planned a Phase 1/2 trial of SGX203 in 2012; RiVax Phase 1B results were expected in the second half of 2012.
- A 1-for-20 reverse stock split became effective February 1, 2012. Shareholders approved increasing authorized common shares from 20 million to 50 million. Common shares outstanding were 11,132,544 at June 30.
Liquidity, outlook and risks
Management believed existing cash, grant-funded program proceeds, headcount reductions and expected New Jersey tax-certificate proceeds would fund working capital and capital expenditures into the third quarter of 2013. This is an estimate dependent on those resources and spending assumptions. Approximately $5.0 million of active grant funding remained available to support programs into 2014. Management also said it may pursue public or private equity financing, with no assurance of availability or favorable terms, and expected continued use of equity to compensate some vendors and partners.
For the next 12 months, the company estimated research and development expenditures of approximately $3.3 million before grant reimbursements ($1.3 million BioTherapeutics and $2.0 million Vaccines/BioDefense), with approximately $2.1 million in grant revenue expected to offset R&D costs. On July 17, 2012, it announced a NIAID SBIR grant expected to provide approximately $600,000 over two years for OrbeShield preclinical development.
Key risks include clinical and regulatory uncertainty, dependence on grants and future financing, and the possibility that programs will not advance or yield commercial products. The filing reports approximately $365,000 in licensing-related commitments, potentially subject to milestones or royalties upon clinical or commercial success, plus aggregate contractual obligations of $684,292 over the next five years. Management reported disclosure controls were effective and identified no additional risk factors beyond those previously disclosed.
Important facts for investors to verify
- Whether cash use and grant receipts support the stated runway into Q3 2013, and whether anticipated New Jersey tax-certificate proceeds are realized.
- Progress and funding for SGX203, SGX201, RiVax, VeloThrax and OrbeShield, including the timing and results of planned clinical or preclinical work.
- Whether additional equity financing is required, its terms, and potential dilution; also review outstanding options and warrants.
- How grant revenue, grant availability and R&D reimbursements develop, given that revenue is principally grant-funded rather than product sales.
- Any further consequences of the failed orBec acute GI GVHD trial, including program costs, intellectual-property carrying values and potential licensing milestones.